RNS Hotlist: AMTE, ANGLE, ATOME. Bushveld, Cambridge, Celadon, Dekel, Fintel, Fusion, Kazera, Microlise, Oberon, Sareum, Tekcapital

07:01, 28th July 2022

AMTE Power (AMTE), the developer and manufacturer of lithium-ion and sodium-ion battery cells, announce that it has approved a new execution strategy and identified Dundee, Scotland as the preferred site for its first MegaFactory. The company said the MegaFactory will be a platform from which AMTE can harness its advanced inhouse capabilities to build manufacturing plants to meet the huge demand for battery cells - allowing it to rapidly scale up production and fast-track the path to achieving net zero.

Bushveld Minerals (BMN), the primary vanadium producer and energy storage solutions group, provided an operational update for the three months and six months ending 30 June 2022. The company said it is on target to meet the annualised steady state production run rate of between 5,000 mtVp.a. and 5,400 mtVp.a. by the end of 2022.

Microlise Group (SAAS), a provider of transport management software to fleet operators, provided a half year update on trading for the six months to June 30, 2022.  Its annual Recurring Revenue run rate as of 30 June 2022 up 10.5% to £40.2m (30 June 2021: £36.4m). Net cash at Period end of £15.8m, up 19% since 31 December 2021 The Group expects to publish its interim results in late September.

Cambridge Cognition (COG), which develops and markets digital solutions to assess brain health, announced two agreements in a new therapeutic area for the Company, PTSD.  Most recently, a research agreement was entered into with the with the United States Department of Defense, following on from a contract secured earlier this year with a top 10 pharmaceutical company.  Approximately 20 PTSD treatment trials run every year, demonstrating the potential for further sales in this therapeutic area.

Tekcapital (TEK), the UK intellectual property investment group, announced its results for the six-month period ended 31 May 2022. Net Assets increased 13% to $76.9m (30 November 2021: $68.1m). NAV per share increased 6% to $0.51 (30 November 2021: $0.48). The company said it was “glad” to report solid half-year performance. Its key portfolio companies are all revenue generating, progressing well, have capable management, and should reach significant additional milestones by the end of 2022.

Sareum Holdings (SAR), the specialist drug development company, announced that it has submitted an application for a Clinical Trial Authorisation to the UK Medicines and Healthcare Products Regulatory Agency for the development of SDC-1801 as a potential new therapeutic for a range of autoimmune diseases with a focus on psoriasis. The company said The CTA application for SDC-1801 is an important milestone as it advances a promising potential new therapeutic into the clinic.

Kazera Global (KZG), the AIM quoted investment company, said that the Department of Mining and Mineral Resources has dismissed a third party's appeal against the grant of a mining permit to the Company's 60% owned subsidiary Whale Head Minerals (Pty)Ltd.  WHM now expects to shortly receive final documentation allowing it to commence production operations of heavy mineral sands at the Walviskop mine in South Africa. The company said ore production from the JORC compliant resource at the Walviskop mine is expected to generate positive cashflow from operations within six months of receipt of the Mining Permit being granted over a 5Ha beach sand deposit at Walviskop.

ATOME Energy (ATOM), the international green hydrogen and ammonia production company, announced another step on the road to delivering its 400MW green hydrogen and ammonia projects in Paraguay. The company said the entry into the FEED contract is the next step in what will in due course culminate in an aggregate of 400MW of green hydrogen and ammonia production in Paraguay, the first phase of which at Villeta is expected to commence production by Q1 2025.

Oberon Investments Group (OBE), the boutique investment management and corporate broking group, announced its results for the year ended 31 March 2022.  Funds under Management and Administration increased 80% to in excess of £1bn (2021: £550m). Revenue increased 75% to £6.7m  (2021: £3.8m) with growth across all divisions. EBITDA loss reduced by 63% to £236,118 (2021: £632,757). The company said that while the current markets and macro-economic conditions are demanding, the Board is focussed on picking opportunities, controlling costs and seeking both organic and acquisitive growth for the next 12 months and beyond.

Celadon Pharmaceuticals (CEL), a UK-based pharmaceutical company, confirmed that it has reappointed Tessera Investment Management Limited as a strategic adviser to the Group. Tessera's original strategic advisory mandate with the Company commenced on 15 January 2021 and concluded on the successful listing of Celadon on 28 March 2022.

ANGLE (AGL), a liquid biopsy company, is pleased announce details of a new separate study from the world-class research team led by Prof. Evi Lianidou at the National and Kapodistrian University of Athens, Greece. The study used the Parsortix® system to harvest CTCs from whole blood samples from 46 early-stage non-small cell lung cancer (NSCLC) patients, to analyse the expression of Metabolism-Related Genes (MRGs). Use of the biomarker-independent Parsortix system also allowed the researchers to investigate the association of MRG expression with epithelial and epithelial to mesenchymal transition (EMT) markers.

Dekel Agri-Vision (DKL), the West African agriculture company, provided an update on the ramp-up of production of its cashew processing plant at Tiebissou, Côte d'Ivoire. The company said the Cashew Operation has advanced considerably over the past 6 weeks and is set to deliver both operational cash flow in Q4 2022 onwards and a material increase in Group revenue and profitability in 2023, the first full year of cashew production.

GreenX Metals (GRX) presented its Quarterly Activities Report for the period during and subsequent to 30 June 2022. The company said it has a cash balance at 30 June 2022 of A$6.1 million to fund activities at ARC plus A$8.3 million available to continue pursuing GreenX's dispute against the Republic of Poland.

Fusion Antibodies (FAB), specialists in pre-clinical antibody discovery and having a stock with a wide spread, announced the appointment of Dr Adrian Kinkaid as Chief Executive Officer, effective from Monday 15 August 2022. Adrian's appointment follows an extensive formal search process further to the Company's announcement on 14 March 2022. Given the historic silence in PR terms, it is to be hoped Mr Kinkaid will have some time to communicate with information hungry shareholders once he gets his feet under the desk.

Fintel (FNTL), a provider of fintech and support services to the UK Retail Financial Services sector, issued a trading update for the first six months of the year. The company said the business has continued to trade well with increasing regulation driving market demand for Fintel’s unique services and fintech offering. Strong Core revenue growth of 9% was in line with the Board’s expectations and outpaced the revenue impact of strategic disposals. Meanwhile, earnings quality continues to grow in absolute terms with the continued digitisation of the Business and successful conversion and scaling of Distribution as a Service (DaaS) revenues.


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles